Oncolytics Biotech Competitors and Similar CompaniesClear all

Oncolytics Biotech's competitors and similar companies include Achilles Therapeutics, Loxo Oncology and Epizyme.

	Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.	Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.	Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
Founding Date	Founding Date 1998	Founding Date 2016	Founding Date 2013	Founding Date 2007
Type	Type Public	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations Calgary, CA HQ Calgary, CA San Diego, US	Locations London, GB HQ Stevenage, GB	Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US	Locations Cambridge, US HQ
Employees	Employees 28	Employees 695% decrease	Employees 65610% decrease	Employees 20364% increase
Valuation ($)	Valuation ($) 93.9 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 250.8 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $37.4m (FY, 2021)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $10.5m (FY, 2021)
Net income	Net income ($28.8m) (FY, 2025)	Net income ($69.7m) (FY, 2023)	Net income ($148.9m) (FY, 2017)	Net income ($251.1m) (FY, 2021)
Funding
Total funding raised	Total funding raised $ 24m	Total funding raised $ 138.1m	Total funding raised $ 57m	Total funding raised $ 51.5m